BRPI0516746A - 5-heterociclil pirimidinas para inibição de hiv - Google Patents

5-heterociclil pirimidinas para inibição de hiv

Info

Publication number
BRPI0516746A
BRPI0516746A BRPI0516746-9A BRPI0516746A BRPI0516746A BR PI0516746 A BRPI0516746 A BR PI0516746A BR PI0516746 A BRPI0516746 A BR PI0516746A BR PI0516746 A BRPI0516746 A BR PI0516746A
Authority
BR
Brazil
Prior art keywords
substituted
optionally substituted
alkyl
amino
alkyloxy
Prior art date
Application number
BRPI0516746-9A
Other languages
English (en)
Inventor
Jerome Emile Georges Guillemont
Jan Heeres
Paulus Joannes Lewi
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of BRPI0516746A publication Critical patent/BRPI0516746A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

5-HETEROCICLIL PIRIMIDINAS PARA INIBIçãO DE HIV. Inibidores da replicação de HIV da fórmula (1), N-óxidos, sais de adição farmaceuticamente aceitáveis, aminas quaternárias ou formas estereoisoméricas dos mesmos, em que: a˜ = a - a = a¬ 4¬ é CH=CH-CH=CH-, -N=CH-CH=CH, -N=CH-N=CH-, -N=CH-CH=N, -N=N-CH=CH-; -b˜ = b - b = b¬ 4¬ é -CH=CH-CH=CH, -N=CH-CH=CH, -N=CH-N=CH, -N=CH-CH=N-, -N=N-CH=CH-; R˜ é hidrogênio; arila; formila; C~ 1~-C~ 6~ alquilcarbonila; C~ 1~-C~ 6~ alquila opcionalmente substituída; C~ 1~-C~ 6~ alquilóxicarbonila; R é OH; halo; C~ 2~-C~ 6~ alquenila ou C~ 2~-C~ 6~ alquinila opcionalmente substituída; carbonila substituída; carboxila; CN; nitro; amino;amino substituído; polihalometila; poilhalometiltio; -S(=O)rR¬ 6¬; C(=NH)R¬ 6¬; R¬ 2a¬ é CN; amino; amino substituído; C~ 1~-C~ 6~ alquila opcionalmente substituída; halo; C~ 1-6~ alquilóxi opcionalmente substituído; carbonila substituída; -CH=N-NH-C (=O)-R16; C~ 1-6~ alquilóxi C~ 1-6~ alquila opcionalmente substituída; C~ 2-6~ alquenila ou C~ 2-6~ alquinila opcionalmente substituída; -C(=N-O-R8)-C~ 1-4~ alquila; R¬ 7¬ ou X~ 1~ é -NR˜-,-O-, -C(=))-, CH~ 2~, -CHOH-,-S-, -S(=O)r-; R é CN; amino; C~ 1~-C~ 6~ alquila; halo; C~ 1~-C~ 6~ alquilóxi opcionalmente substituído; carbonila substituída; -CH=N-NH-C(=O)-R¬ 16¬; C~ 1~-C~ 6~ alquila substituída; C~ 1~-C~ 6~ alquilóxi C~ 1~-C~ 6~ alquila opcionalmente substituída; -C~ 2~-C~ 6~ alquenila ou C~ 2~ -C~ 6~ alquinila opcionalmente substituída; -C(=N-O-R¬ 8)-C~ 1-4~ alquila; R¬ 7¬; -X~ 3~-R¬ 7¬; R¬ 4¬ é halo; OH; C~ 1-6~ alquila opcionalmente substituída; C~ 2-6~ alquenila ou C~ 2-6~ alquinila; C~ 3-7 cicloalquila; C~ 1-6~ alquilóxi; CN; nitro; polihalo C~ 1-6~ alquila; polihalo C~ 1-6~ alquilóxi; carbonila substituída; formila; amino; mono- ou di(C~ 1-4~ alquil)amino ou R¬ 7¬; R¬ 5¬ é um sistema de anel completamente insaturado de 5 ou 6 elementos, em que 1-4 elementos no anel são nitrogênio, oxigênio ou enxofre; anel o qual pode ser opcionalmente substituído e pode ser opcionalmente anelado a um anel de benzeno; métodos para seu preparo e composições farmacêuticas compreendendo os mesmos. A presente invenção também se refere ao uso desses compostos para a prevenção ou tratamento de infecção pelo HIV.
BRPI0516746-9A 2004-09-30 2005-09-29 5-heterociclil pirimidinas para inibição de hiv BRPI0516746A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04104812 2004-09-30
PCT/EP2005/054930 WO2006035067A2 (en) 2004-09-30 2005-09-29 Hiv inhibiting 5-heterocyclyl pyrimidines

Publications (1)

Publication Number Publication Date
BRPI0516746A true BRPI0516746A (pt) 2008-09-23

Family

ID=34929638

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516746-9A BRPI0516746A (pt) 2004-09-30 2005-09-29 5-heterociclil pirimidinas para inibição de hiv

Country Status (17)

Country Link
US (1) US8575342B2 (pt)
EP (1) EP1797069B1 (pt)
JP (1) JP5008567B2 (pt)
KR (1) KR20070057899A (pt)
CN (1) CN101031558B (pt)
AR (1) AR050969A1 (pt)
AT (1) ATE520680T1 (pt)
AU (1) AU2005288864B2 (pt)
BR (1) BRPI0516746A (pt)
CA (1) CA2577467C (pt)
ES (1) ES2371923T3 (pt)
IL (1) IL180959A (pt)
MX (1) MX2007003797A (pt)
RU (1) RU2405778C2 (pt)
TW (1) TW200626574A (pt)
WO (1) WO2006035067A2 (pt)
ZA (1) ZA200702653B (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626574A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
CN101027288B (zh) 2004-09-30 2013-04-17 泰博特克药品有限公司 抑制hiv的5-取代嘧啶
AU2006215599B2 (en) * 2005-02-18 2012-09-27 Janssen Sciences Ireland Uc HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CA2645958C (en) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
CN101553483B (zh) 2006-12-13 2013-04-17 弗·哈夫曼-拉罗切有限公司 作为非核苷逆转录酶抑制剂的2-(哌啶-4-基)-4-苯氧基-或苯基氨基-嘧啶衍生物
EP2114902B1 (en) 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv inhibiting 5,6-substituted pyrimidines
US9006243B2 (en) 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines
TW201016676A (en) * 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
FI3392252T3 (fi) 2011-08-23 2024-01-08 Libertas Bio Inc Pyrimidopyridazinoniyhdisteet ja niiden käyttö
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
JP2015517574A (ja) * 2012-05-22 2015-06-22 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル がん治療のためのピリミジン化合物
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
EP2925752A4 (en) 2012-11-27 2016-06-01 Univ North Carolina PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
RU2547844C1 (ru) * 2013-10-29 2015-04-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук Способ получения 5-(гет)арил-4-(2-тиенил)-2-(тио)морфолилпиримидина
WO2015157122A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrazolopyrimidine compounds
RS58124B1 (sr) * 2014-04-28 2019-02-28 Medicines For Malaria Venture Mmv Triaminopirimidin jedinjenja korisna za prevenciju ili tretman malarije
TWI803187B (zh) * 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
EP3615032A4 (en) 2017-04-28 2020-12-23 Asana BioSciences, LLC FORMULATIONS, PROCEDURES, KITS AND DOSING FORMS FOR TREATMENT OF ATOPIC DERMATITIS AND IMPROVED STABILITY OF AN ACTIVE INGREDIENT
WO2019222538A1 (en) * 2018-05-16 2019-11-21 The University Of North Carolina At Chapel Hill Aminopyrimidines and aminopyridines as mertk inhibitors and their application in cancer treatment
WO2021167495A1 (en) 2020-02-19 2021-08-26 Pharmasyntez, Joint Stock Company Pyrimidine-based bicycles as antiviral agents for the treatment and prevention of hiv infection
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022059996A1 (ko) * 2020-09-15 2022-03-24 서울대학교 기술지주 주식회사 혈액 순환 미세체외소체 매개 암 치료용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
CZ154398A3 (cs) 1995-11-23 1998-08-12 Janssen Pharmaceutica N.V. Pevné směsi cyklodextrinů připravené vytlačováním taveniny
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
KR100699514B1 (ko) 1998-03-27 2007-03-26 얀센 파마슈티카 엔.브이. Ｈｉｖ를 억제하는 피리미딘 유도체
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
EA004049B1 (ru) 1998-11-10 2003-12-25 Янссен Фармацевтика Н.В. Пиримидины, ингибирующие репликацию вич
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
WO2001058700A1 (de) 2000-02-14 2001-08-16 Claus Rayhle Klammer
JP5230050B2 (ja) * 2000-05-08 2013-07-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ複製阻害剤
ES2266095T3 (es) 2000-12-21 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de la proteina quinasa.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
MXPA05005146A (es) 2002-11-15 2005-07-22 Tibotec Pharm Ltd Indolpiridinio sustituido como compuestos antiinfecciosos.
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2403244C2 (ru) 2004-09-30 2010-11-10 Тиботек Фармасьютикалз Лтд. Вич-ингибирующие 5-карбо- или гетероциклические замещенные пиримидины
CN101027288B (zh) 2004-09-30 2013-04-17 泰博特克药品有限公司 抑制hiv的5-取代嘧啶
TW200626574A (en) 2004-09-30 2006-08-01 Tibotec Pharm Ltd HIV inhibiting 5-heterocyclyl pyrimidines
CA2645958C (en) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
EP2114902B1 (en) 2006-12-29 2014-09-17 Janssen R&D Ireland Hiv inhibiting 5,6-substituted pyrimidines
US9006243B2 (en) 2006-12-29 2015-04-14 Janssen R&D Ireland HIV inhibiting 6-substituted pyrimidines

Also Published As

Publication number Publication date
JP2008514679A (ja) 2008-05-08
IL180959A (en) 2012-08-30
CA2577467A1 (en) 2006-04-06
EP1797069A2 (en) 2007-06-20
ES2371923T3 (es) 2012-01-11
WO2006035067A2 (en) 2006-04-06
US20090181993A1 (en) 2009-07-16
CA2577467C (en) 2013-05-28
AU2005288864B2 (en) 2012-08-23
RU2405778C2 (ru) 2010-12-10
WO2006035067A3 (en) 2006-08-24
CN101031558B (zh) 2011-10-05
AR050969A1 (es) 2006-12-06
CN101031558A (zh) 2007-09-05
ATE520680T1 (de) 2011-09-15
ZA200702653B (en) 2008-08-27
KR20070057899A (ko) 2007-06-07
TW200626574A (en) 2006-08-01
MX2007003797A (es) 2007-04-23
JP5008567B2 (ja) 2012-08-22
US8575342B2 (en) 2013-11-05
RU2007116152A (ru) 2008-11-10
IL180959A0 (en) 2007-07-04
AU2005288864A1 (en) 2006-04-06
EP1797069B1 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
BRPI0516746A (pt) 5-heterociclil pirimidinas para inibição de hiv
BRPI0515935A (pt) pirimidinas heterociclil - ou 5-carbo substituìdas para inibição de hiv
BRPI0517272A (pt) derivados de pirimidina bicìclicos de inibição de hiv
BR0213522B1 (pt) compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto
NO983687L (no) Kinazolin-derivater som VEGF-inhibitorer
WO2002032900A3 (en) Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents
RS52061B (en) PIRAZOLYL-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS
HK1070359A1 (en) Benzimidazole derivatives and their use as gnrh antagonists
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
BR112014000563A2 (pt) composto, composição farmacêutica, e, uso do composto
PT892793E (pt) Derivados 2-cianoiminoimidazolo inibidores da pde iv
WO2007127725A3 (en) Diazeniumdiolated non-steroidal anti-inflammatory drugs, compositions thereof, and related methods
BR0211171A (pt) Compostos quìmicos
DK1858861T3 (da) HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
WO2005120516A3 (en) Hiv integrase inhibitors
MY137083A (en) Non-nucleoside reverse transcriptase inhibitors
BR0208824A (pt) Composto, métodos de tratamento de distúrbios que são remediados ou aliviados por atividade de agonista de vasopressina em um mamìfero, e de indução de retardamento temporário de urinação em um mamìfero, e, composição farmacêutica
MY138996A (en) 4-amino-5-cyanopyrimidine derivatives
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
ATE512964T1 (de) N8,n13-disubstituierte chinoä4,3,2,klüacridinium salze als arzneimittel
WO2002080918A1 (fr) Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
DK1802581T3 (da) 4-[(2,4-Dichlor-5-methoxyphenyl)amino]-6-alkoxy-7-ethynyl-3-quinolincarbonitriller til behandling af iskæmisk beskadigelse
WO2008047138A3 (en) Histone deacetylase inhibitors
SE0102867D0 (sv) Non-nucleoside reverse transcriptase inhibitors
EP1747200B8 (en) Alkaloid compounds and their use as anti-malarial drugs

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time